Among all tumor types, skin cancers are profoundly sensitive to immunotherapy. Indeed, the
recently reported response rates for anti-PD-1 (anti-programmed-death 1) therapy for …

Uveal melanoma is considered a rare disease but it is the most common intraocular
malignancy in adults. Local treatments are effective, but the systemic recurrence rate is …

Prognostication is the science by which clinicians estimate a patient's expected outcome. A
robust literature shows that many patients with advanced cancer have inaccurate …

PURPOSE Many immune checkpoint inhibitors (ICIs) have been approved on the basis of
tumor response end points in nonrandomized trials, including objective response rate (ORR) …

Background Long-term responders have been observed with anti-programmed death 1 and
anti-programmed death ligand 1 (anti-PD (L) 1). Optimal duration of therapy in responding …

Immune checkpoint inhibitors (ICIs) are a revolutionary breakthrough in the field of cancer by
modulating patient's own immune system to exert anti-tumor effects. The clinical application …

Abstract Purpose Immune checkpoint inhibitors (ICIs) and targeted therapy (TT) have
improved the survival of people with metastatic melanoma. We assessed the feasibility …

An 83-year-old patient developed erosions and a blister of the gingival mucous membrane,
6 months after discontinuation of the anti-programmed death-1 (anti PD-1) pembrolizumab …

Melanoma has been the most important cancer to drive immunotherapy development of
solid tumors. Since 2010, immunotherapy has been revolutionized by the concept of …

Cancer immunotherapy has fundamentally altered cancer treatment; however, its efficacy is
limited to a subset of patients in most clinical settings. The immune system plays a key role …